Related Experiment Videos
[Cytomegalovirus infections after kidney transplantation and passive immunization]
Abstract:
Cytomegalovirus infection after renal transplantation impairs the survival rate of patient and graft. An incidence of 24 to 92% of CMV infections after renal transplantation is reported, but only 15 to 77% of these patients show clinical symptoms. Contaminated donor organs, blood transfusions and reactivation by immunosuppression are the main causes of this infection. Active immunisation cannot prevent the reactivation of the infection, but also antiviral agents can hardly influence the course of the disease. Passive immunisation showed promising effects in bone-marrow transplantation and is now also tried in renal transplantation. The first results of a randomized study do not allow a final conclusion, but show less clinical symptomatic CMV infections, and statistically significant less herpes simplex infections in the group receiving anti CMV IgG prophylaxis.
Insights
Cytomegalovirus (CMV) infection negatively impacts kidney transplant survival. Passive immunization with anti-CMV IgG prophylaxis may reduce symptomatic CMV and herpes simplex infections post-transplant.
Area of Science:
- Nephrology
- Transplantation Immunology
- Infectious Diseases
Background:
- Cytomegalovirus (CMV) infection is a significant complication following renal transplantation, affecting patient and graft survival.
- Incidence rates of CMV infection range from 24% to 92%, with only 15% to 77% of cases presenting with clinical symptoms.
- Primary causes include contaminated donor organs, blood transfusions, and CMV reactivation due to immunosuppression.
Purpose of the Study:
- To evaluate the efficacy of passive immunization with anti-CMV IgG in preventing or mitigating CMV infection after renal transplantation.
- To assess the impact of anti-CMV IgG prophylaxis on clinical outcomes, including symptomatic CMV disease and other infections.
Main Methods:
- A randomized study was conducted to compare outcomes between renal transplant recipients receiving anti-CMV IgG prophylaxis and a control group.
- Data on CMV infection incidence, clinical symptoms, and co-infections were collected and analyzed.
Main Results:
- While not allowing a definitive conclusion, the study indicated a reduction in clinically symptomatic CMV infections in the prophylaxis group.
- A statistically significant decrease in herpes simplex virus infections was observed in patients receiving anti-CMV IgG prophylaxis.
Conclusions:
- Passive immunization with anti-CMV IgG shows potential as a prophylactic strategy in renal transplantation.
- Further research is warranted to confirm the benefits and establish optimal protocols for anti-CMV IgG use in this patient population.